Wall Street Analyst Initiated Werewolf Therapeutics Inc [HOWL]. What else is Wall St. saying

BITF

Werewolf Therapeutics Inc [NASDAQ: HOWL] traded at a high on Monday, posting a 39.02 gain after which it closed the day’ session at $2.85.

The results of the trading session contributed to over 9925239 shares changing hands. Over the past one week, the price volatility of Werewolf Therapeutics Inc stands at 10.04% while the volatility over the past one month is 7.70%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The market cap for HOWL stock reached $124.54 million, with 39.11 million shares outstanding and 30.40 million shares in the current float. Compared to the average trading volume of 160.79K shares, HOWL reached a trading volume of 9925239 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Werewolf Therapeutics Inc [HOWL]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HOWL shares is $12.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HOWL stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

JMP Securities have made an estimate for Werewolf Therapeutics Inc shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on April 03, 2024. While these analysts kept the previous recommendation, Wedbush raised their target price to Outperform. The new note on the price target was released on August 24, 2023, representing the official price target for Werewolf Therapeutics Inc stock. Previously, the target price had yet another raise from $11 to $12, while Jefferies kept a Buy rating on HOWL stock.

The Average True Range (ATR) for Werewolf Therapeutics Inc is set at 0.22, with the Price to Sales ratio for HOWL stock in the period of the last 12 months amounting to 13.42. The Price to Book ratio for the last quarter was 1.20, with the Price to Cash per share for the same quarter was set at 3.10.

How has HOWL stock performed recently?

Werewolf Therapeutics Inc [HOWL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 45.41. With this latest performance, HOWL shares gained by 30.14% in over the last four-week period, additionally sinking by -53.20% over the last 6 months – not to mention a rise of 41.79% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HOWL stock in for the last two-week period is set at 74.48, with the RSI for the last a single of trading hit 83.67, and the three-weeks RSI is set at 66.85 for Werewolf Therapeutics Inc [HOWL]. The present Moving Average for the last 50 days of trading for this stock 2.12, while it was recorded at 2.20 for the last single week of trading, and 4.10 for the last 200 days.

Werewolf Therapeutics Inc [HOWL]: Deeper insight into the fundamentals

Werewolf Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.13 and a Current Ratio set at 12.13.

Earnings analysis for Werewolf Therapeutics Inc [HOWL]

With the latest financial reports released by the company, Werewolf Therapeutics Inc posted -0.23/share EPS, while the average EPS was predicted by analysts to be reported at -0.39/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.16. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HOWL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Werewolf Therapeutics Inc go to 10.90%.

Insider trade positions for Werewolf Therapeutics Inc [HOWL]

The top three institutional holders of HOWL stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 6.14 million shares, which is approximately 14.7688%. MPM ASSET MANAGEMENT LLC, holding 4.28 million shares of the stock with an approximate value of $$10.45 million in HOWL stocks shares; and MPM ASSET MANAGEMENT LLC, currently with $$7.91 million in HOWL stock with ownership which is approximately 7.7897%.